14 recruiting, 4 not yet recruiting, 2 completed, 1 terminated. 11 Phase 2, 4 Phase 3, 2 Not applicable, 2 Phase 1.
Follow Hepato Cellular Carcinoma (HCC): new trials by email Literature Review of Hepato Cellular Carcinoma (HCC) trials Research Report on Hepato Cellular Carcinoma (HCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC WGI-0301, Nivolumab (240 mg) - Hepato Cellular Carcinoma (HCC), Renal Cell Cancer | Phase 2 | Not yet recruiting | Zhejiang Haichang Biotech Co., Ltd. | 230 | 2026-06-01 | 2026-03-27 |
| Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma MRG003 - Hepato Cellular Carcinoma (HCC) | Phase 2 | Recruiting | Fudan University | 40 | 2026-04-17 | 2026-04-21 |
| Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection Atezolizumab - Hepato Cellular Carcinoma (HCC), Immunotherapy | Phase 3 | Not yet recruiting | University of Geneva, Switzerland | 30 | 2026-03-25 | 2026-03-10 |
| TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk sintilimab, ipilimumab N01, Lenvatinib - Hepato Cellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 105 | 2026-03-18 | 2026-03-27 |
| Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma DEB-DoxNic-TACE, current standard of care - Hepato Cellular Carcinoma (HCC) | Phase 2 / Phase 3 | Recruiting | University Hospital, Basel, Switzerland | 152 | 2026-02-16 | 2026-03-02 |
| A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI - Hepato Cellular Carcinoma (HCC) | Phase 2 | Recruiting | Fudan University | 350 | 2026-01-19 | 2026-04-21 |
| Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab Fecal microbiota transplantation (FMT), Atezolizumab & Bevacizumab - Hepato Cellular Carcinoma (HCC) | Phase 2 | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 15 | 2026-01-01 | 2026-06-01 |
| Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) Ambulatory care, Conventional inpatient care - Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma | Not applicable | Recruiting | University Hospital, Angers | 206 | 2025-12-18 | 2026-07-17 |
| SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin Topical Indomethacin - Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome | Phase 2 | Recruiting | National Taiwan University Hospital | 39 | 2025-12-09 | 2026-05-01 |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma BC3402, Durvalumab, Tremelimumab - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-11-01 | 2026-02-19 | |
| Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib - Hepato Cellular Carcinoma (HCC), Chemotherapy Effect | Phase 3 | Recruiting | Linhui Peng | 326 | 2025-10-31 | 2025-12-16 |
| Retrospective Clinical Validation of HepatoPredict Hepato Cellular Carcinoma (HCC), Liver Resection | Not yet recruiting | Ophiomics | 200 | 2025-03-01 | 2025-03-25 | |
| Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma fibroscan - Hepato Cellular Carcinoma (HCC) | Recruiting | Tanta University | 80 | 2025-01-26 | 2025-05-07 | |
| PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma Prothrombin induced by vitamin K absence II (PIVKA-II) - Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis | Recruiting | Tanta University | 116 | 2025-01-15 | 2025-05-07 | |
| HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery - Hepato Cellular Carcinoma (HCC) | Phase 2 | Recruiting | Fudan University | 165 | 2025-01-01 | 2025-02-06 |
| The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation Sedation using combination of Propofol and Fentanyl., Sedation using combination of Propofol and Fentanyl and lidocaine - Hepato Cellular Carcinoma (HCC), Sedation and Analgesia | Not applicable | Recruiting | Iuliu Hatieganu University of Medicine and Pharmacy | 100 | 2024-11-12 | 2026-07-21 |
| PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC PD-L1 antibody, Bevacizumab, HAIC-FOLFOX - Hepato Cellular Carcinoma (HCC) | Phase 2 | Recruiting | West China Hospital | 36 | 2024-10-01 | 2024-12-19 |
| Hepatocellular Carcinoma Identification Using Delta-HLD Hepato Cellular Carcinoma (HCC) | Recruiting | Epiliquid Holding, Inc | 200 | 2023-05-18 | 2025-09-09 | |
| Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence Hypothermic Oxygented Perfusion, Static Cold Storage - Liver Carcinoma, Liver Transplant | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 237 | 2022-06-03 | 2025-01-30 | |
| Evaluate the Effect of Tirazamine on Primary Liver Cancer. tirapazamine, Transarterial Embolization, TACE - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Zhejiang Raygene Pharmaceuticals Co., Ltd | 16 | 2021-05-14 | 2025-02-27 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Hepatocellular (9) · Liver Neoplasms (2) · Agnosia (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Patient Satisfaction (1) · Recurrence (1)
Neoplasms (12) · Neoplasms by Site (12) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Liver Diseases (11) · Adenocarcinoma (10) · Carcinoma (10) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Liver Neoplasms (9) · Pathological Conditions, Signs and Symptoms (2) · Behavior (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Bevacizumab (2) · atezolizumab (2) · lenvatinib (2) · sintilimab (2) · Ambulatory Care (1) · Fecal Microbiota Transplantation (1) · Fentanyl (1) · Indomethacin (1) · Lidocaine (1) · Nivolumab (1) · Sorafenib (1) · Surgical Procedures, Operative (1) · Tirapazamine (1) · XELOX (1) · apatinib (1)
Fudan University (3) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Tanta University (2) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Epiliquid Holding, Inc (1) · Haitao Zhao, MD (1) · Iuliu Hatieganu University of Medicine and Pharmacy (1) · Linhui Peng (1) · National Taiwan University Hospital (1) · Ophiomics (1) · Sun Yat-sen University (1) · University Hospital, Angers (1) · University Hospital, Basel, Switzerland (1) · University of Geneva, Switzerland (1)
China (9) · Italy (3) · Argentina (2) · Egypt (2) · France (2) · Switzerland (2) · Taiwan (2) · United States (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Germany (1) · Hong Kong (1)
Caifang Ni, M.D (1) · Fahim Ebrahimi, PD Dr. (1) · Matteo Ravaioli, MD (1) · Nabila A Elgazzar, MD (1) · Rania M Elkafoury, MD (1) · Yu-Yun Shao, M.D., Ph.D. (1)
PMID 20175034, PMID 23980084, PMID 24561446, PMID 28990587, PMID 29375202, PMID 30207593, PMID 33141959, PMID 33510460, PMID 34052255, PMID 35999856, PMID 38270476, PMID 38768472, PMID 39986353, PMID 41125112, PMID 42562579, PMID 5095567, PMID 8569837
2023 (1)